Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiovascular Diseases AND Acute Coronary Syndrome AND Placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    58 result(s) found for: Cardiovascular Diseases AND Acute Coronary Syndrome AND Placebo. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2011-005698-21 Sponsor Protocol Number: EFC11570 Start Date*: 2013-03-05
    Sponsor Name:sanofi-aventis Recherche & Développement
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recentl...
    Medical condition: Acute coronary syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) BE (Completed) NO (Completed) EE (Completed) LT (Completed) HU (Completed) ES (Completed) CZ (Completed) LV (Completed) DE (Completed) IT (Completed) BG (Completed) FI (Completed) AT (Completed) PT (Completed) DK (Completed) NL (Completed) PL (Completed) SK (Completed) SI (Completed) HR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-001959-11 Sponsor Protocol Number: CL3-16257-056 Start Date*: 2005-04-20
    Sponsor Name:Institut de Recherches Internationales
    Full Title: Effects of ivabradine on cardiovascular events in patients with stable coronary artery disease and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled int...
    Medical condition: Coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    7.0 10011078 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) FI (Completed) LV (Completed) IT (Completed) CZ (Completed) SK (Completed) GB (Completed) DK (Completed) AT (Completed) SE (Completed) EE (Completed) DE (Completed) IE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-008298-77 Sponsor Protocol Number: CV185-068 Start Date*: 2009-04-14
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome
    Medical condition: Subjects with a recent acute coronary syndrome (ACS) and at least 2 additional risk factors for recurrent ischemic events.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051592 Acute coronary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) NO (Completed) ES (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) DK (Completed) CZ (Prematurely Ended) BE (Completed) HU (Prematurely Ended) DE (Completed) BG (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023467-18 Sponsor Protocol Number: CTSUREVEAL1 Start Date*: 2011-01-25
    Sponsor Name:University of Oxford
    Full Title: REVEAL: Randomized EValuation of the Effects of Anacetrapib through Lipid-modification. A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with e...
    Medical condition: Atherosclerotic cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DK (Completed) FI (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000296-15 Sponsor Protocol Number: E5555-G000-202 Start Date*: 2007-11-22
    Sponsor Name:Eisai Limited
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Clinical Events and Biomarkers in Patients with Non-ST-Segment Elevation Acute Coron...
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011078 Coronary artery disease PT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) BE (Completed) DE (Completed) NL (Completed) SE (Completed) CZ (Completed) PL (Completed) IE (Completed) IT (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-000996-98 Sponsor Protocol Number: CSL112_3001 Start Date*: 2018-09-05
    Sponsor Name:CSL Behring LLC
    Full Title: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome
    Medical condition: Acute Coronary Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted) LV (Completed) SE (Completed) PT (Completed) FI (Completed) BE (Completed) LT (Completed) DK (Completed) EE (Completed) DE (Completed) AT (Completed) CZ (Completed) NO (Completed) HU (Completed) FR (Completed) NL (Completed) ES (Restarted) SK (Completed) BG (Completed) GR (Completed) HR (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-012852-26 Sponsor Protocol Number: EFC11319 Start Date*: 2010-09-06
    Sponsor Name:sanofi-aventis Recherche & Développement
    Full Title: Estudio multicéntrico doble ciego, aleatorizado, controlado con placebo y de grupos paralelos, para evaluar los eventos cardiovasculares durante el tratamiento con lixisenatide en pacientes con dia...
    Medical condition: Diabetes tipo II ___________________ Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) PT (Completed) GB (Completed) LT (Completed) EE (Completed) DK (Completed) LV (Completed) IT (Completed) NL (Completed) SE (Completed) FR (Completed) FI (Completed) BG (Completed) BE (Completed) NO (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004301-99 Sponsor Protocol Number: 1160.67 Start Date*: 2008-02-06
    Sponsor Name:Boehringer Ingelheim AB
    Full Title: RandomisEd Dabigatran Etexilate dose finding study in patients with acute coronary syndromes post index Event with additional risk factors for cardiovascular complications also receiving aspirin an...
    Medical condition: Acute coronary syndromes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed) DE (Completed) ES (Completed) BE (Completed) GB (Completed) IE (Completed) CZ (Completed) HU (Completed) FR (Completed) PL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004565-14 Sponsor Protocol Number: 20170625 Start Date*: 2019-09-13
    Sponsor Name:Amgen Inc.
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardia...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) LT (Trial now transitioned) LV (Trial now transitioned) EE (Trial now transitioned) SK (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) IS (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002677-53 Sponsor Protocol Number: CL2-78989-009 Start Date*: 2012-12-19
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S.)
    Full Title: Evaluation of the subcutaneous administration of 30 mg of S 78989 versus placebo and evaluation of the subcutaneous administration of 60 mg of S 78989 versus placebo on the reduction of arterial wa...
    Medical condition: Arterial wall inflammation in patients with marked atherosclerotic plaque inflammation
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004849 10057703 Coronary atherosclerosis of non-autologous biological bypass graft LLT
    16.0 100000004849 10058152 Coronary atherosclerosis of bypass graft LLT
    16.0 100000004866 10018104 Generalized and unspecified atherosclerosis LLT
    16.0 100000004866 10002892 Aortic atherosclerosis LLT
    16.0 100000004849 10011093 Coronary atherosclerosis LLT
    16.0 100000004866 10003603 Atherosclerosis generalized LLT
    16.0 100000004849 10011095 Coronary atherosclerosis of native coronary artery LLT
    16.0 100000004866 10003605 Atherosclerosis of aorta LLT
    16.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    16.0 100000004849 10011094 Coronary atherosclerosis of autologous biological bypass graft LLT
    16.0 100000004849 10011076 Coronary artery atherosclerosis LLT
    16.0 100000004849 10011097 Coronary atherosclerosis of unspecified vessel LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-018173-31 Sponsor Protocol Number: POISE-2 Start Date*: 2011-02-25
    Sponsor Name:Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
    Full Title: Ensayo clínico factorial de clonidina y aspirina en pacientes que van a ser sometidos a cirugía no cardiaca y que estén en riesgo moderado o alto de sufrir eventos cardíacos perioperatorios (Estudi...
    Medical condition: Prevención de episodios cardiovasculares en pacientes de moderado a alto riesgo cardiovascular que son sometidos a una cirugía no cardiaca.
    Disease: Version SOC Term Classification Code Term Level
    9 10007649 Cardiovascular disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) AT (Completed) BE (Completed) DK (Completed) GB (Completed) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000214-19 Sponsor Protocol Number: D5130L00006 Start Date*: 2011-07-13
    Sponsor Name:AstraZeneca
    Full Title: A 30 day international, randomized, parallel-group, double-blind, placebo-controlled phase IV study to evaluate efficacy and safety of pre-hospital vs. in-hospital initiation of ticagrelor therapy ...
    Medical condition: myocardial infarction, STEMI patients planned for Percutaneous Coronary Intervention
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) AT (Completed) SE (Completed) DK (Completed) NL (Completed) ES (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-004129-33 Sponsor Protocol Number: CRC2017EVO Start Date*: 2018-08-02
    Sponsor Name:Friedrich-Alexander-Universtiy Erlangen-Nürnberg, Medical Faculty
    Full Title: Randomized, double-blind, placebo controlled, parallel-group, prospective clinical study to analyse the effect of evolocumab on vascular function.
    Medical condition: atherosclerotic cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004393-22 Sponsor Protocol Number: LIB003-006 Start Date*: 2022-01-13
    Sponsor Name:LIB Therapeutics, LLC
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Cardiovascular Disease, or at High Risk for Cardiovascular Disea...
    Medical condition: Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease, on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002004-24 Sponsor Protocol Number: CV185-316 Start Date*: 2017-02-08
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillatio...
    Medical condition: Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    20.0 10042613 - Surgical and medical procedures 10065608 Percutaneous coronary intervention PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) BG (Completed) AT (Completed) BE (Completed) DK (Completed) NL (Completed) PL (Completed) PT (Completed) ES (Completed) CZ (Completed) DE (Completed) SE (Completed) SK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002856-18 Sponsor Protocol Number: RB12.079 Start Date*: 2013-03-22
    Sponsor Name:CHRU de Brest
    Full Title: ALdosterone antagonist Chronic HEModialysis Interventional Survival Trial
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10050441 Chronic renal insufficiency LLT
    14.1 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012581-32 Sponsor Protocol Number: SB-480848/033 Start Date*: 2010-01-28
    Sponsor Name:GlaxoSmithKline Research & Development, Ltd
    Full Title: A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). (Short title: The Stabi...
    Medical condition: after recent Acute Coronary Syndrome (ACS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) ES (Completed) NL (Completed) SE (Completed) DK (Completed) HU (Completed) CZ (Completed) SK (Completed) PL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001381-26 Sponsor Protocol Number: CER-001-CLIN-010 Start Date*: 2015-07-22
    Sponsor Name:CERENIS THERAPEUTICS SA
    Full Title: A PHASE II MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FOCUSING TRIAL OF CER-001 IN SUBJECTS WITH ACUTE CORONARY SYNDROME
    Medical condition: Acute Coronary Syndrome (ACS) with significant plaque volume
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003486-26 Sponsor Protocol Number: 1002-047 Start Date*: 2017-05-24
    Sponsor Name:Esperion Therapeutics Inc.,
    Full Title: A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients with Hyperlipidemia at High Cardiovascular Risk Not Ad...
    Medical condition: Patients with Hyperlipidemia at High Cardiovascular Risk Not Adequately Controlled by Their Lipid-Modifying Therapy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10007541 - Cardiac disorders 10007648 Cardiovascular disease, unspecified LLT
    20.0 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002040-14 Sponsor Protocol Number: RVX222-CS-015 Start Date*: 2015-10-01
    Sponsor Name:Resverlogix Corp.
    Full Title: A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, up to 104 Weeks Dosing, Placebo- Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects with Coronary Ar...
    Medical condition: Secondary cardiovascular disease (CVD) prevention in type 2 diabetes mellitus (T2DM) subjects with low high-density lipoprotein cholesterol (HDL-C) at high risk for MACE.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10051614 Arteriosclerotic cardiovascular disease LLT
    19.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) DE (Completed) SK (Completed) HR (Completed) PL (Completed) BG (Completed) NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 08:55:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA